Download PDF
Diabetes aktuell 2014; 12(5): 226-231
DOI: 10.1055/s-0034-1393718
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Alte und neue kardiovaskuläre Risikofaktoren bei diabetischer Nephropathie – Ein Update

Traditional and novel risk factors in diabetic nephropathy – an update
Martin Busch
1   Klinik für Innere Medizin III, Klinikum der Friedrich-Schiller-Universität Jena, Jena
› Author Affiliations
Further Information

Publication History

Publication Date:
12 September 2014 (online)

Also available at
    Permissions and Reprints

Patienten mit diabetischer Nephropathie weisen ein deutlich erhöhtes Risiko für kardiovaskuläre Erkrankungen auf. Sowohl Diabetes mellitus als auch die chronische Nierenerkrankung stellen unabhängige kardiovaskuläre Risikofaktoren dar. Infolge Diabetes mellitus ist das Risiko bereits auf das Doppelte erhöht. Das Vorhandensein einer reduzierten glomerulären Filtrationsrate von < 60 ml/min jeglicher Ursache ist mit einem höheren Mortalitätsrisiko als bei Diabetes mellitus assoziiert. Das Risiko steigt in Abhängigkeit des Grades der Nierenfunktionseinschränkung exponentiell an. Beide Erkrankungen gehen zudem mit einer erhöhten Prävalenz klassischer kardiovaskulärer Risikofaktoren einher. Dies erklärt die Risikoerhöhung zum Teil. Diverse neue Biomarker können das Risikoprofil ebenfalls nur bedingt fokussieren. Ihre therapeutische Beeinflussbarkeit ist bislang gering. Die Veränderung des Lebensstils in der Kombination mit einem intensiven medizinischen Management erzielt wahrscheinlich die beste Risikoreduktion. Der Review gibt einen Überblick über konventionelle und neue kardiovaskuläre Risikomarker bei diabetischer Nephropathie.

Patients with diabetic nephropathy have an increased risk of cardiovascular diseases. Both diabetes mellitus and chronic kidney disease are independent cardiovascular risk factors. DM results in a doubling of cardiovascular risk. Any decrease of the glomerular filtration rate below 60 ml/min is associated with a higher mortality risk than diabetes alone. The risk increases exponentially in dependence from the stage of renal disease. Moreover, both diseases are accompanied by an increased prevalence of classical atherosclerotic risk factors which does explain the increase in risk only in part. The impact of several new biomarkers on the risk profile is limited. The therapeutic manipulation of such newer factors is often poor. Probably, lifestyle changes together with an intensive medical management lead to the best results in risk reduction. This review gives an overview of traditional and new cardiovascular risk markers in diabetic nephropathy.

Key words

Diabetes mellitus - chronic kidney disease - diabetic nephropathy - cardiovascular risk - traditional risk factors - novel risk factors
 

  • Literatur

  • 1 Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222
    CrossrefPubMedGoogle Scholar
  • 2 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplement 2013; 3: 1-150
    CrossrefGoogle Scholar
  • 3 Pistrosch F, Natali A, Hanefeld M. Is hyperglycemia a cardiovascular risk factor?. Diabetes Care 2011; 34 (Suppl. 02) 128-131
    CrossrefGoogle Scholar
  • 4 Palsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis 2014; 21: 273-280
    CrossrefGoogle Scholar
  • 5 Tonelli M, Muntner P, Lloyd A et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; 380: 807-814
    CrossrefPubMedGoogle Scholar
  • 6 Marshall SM. Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus. Adv Chronic Kidney Dis 2014; 21: 267-272
    CrossrefGoogle Scholar
  • 7 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
    CrossrefPubMedGoogle Scholar
  • 8 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
    CrossrefGoogle Scholar
  • 9 St Peter WL, Odum LE, Whaley-Connell AT. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy 2013; 33: 496-514
    CrossrefGoogle Scholar
  • 10 Ritz E, Wanner C. Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephrol 2006; 17: 226-230
    CrossrefGoogle Scholar
  • 11 Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
    CrossrefGoogle Scholar
  • 12 Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
    CrossrefGoogle Scholar
  • 13 Kidney Disease Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney International Supplement 2013; 3: 259-305
    CrossrefGoogle Scholar
  • 14 Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33: 1395-1402
    CrossrefGoogle Scholar
  • 15 Drechsler C, Verduijn M, Pilz S et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1752-1759
    CrossrefGoogle Scholar
  • 16 Johnson RJ, Nakagawa T, Jalal D et al. Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transplant 2013; 28: 2221-2228
    CrossrefGoogle Scholar
  • 17 Busch M, Franke S, Ruster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010; 40: 742-755
    CrossrefGoogle Scholar
  • 18 Jamison RL, Hartigan P, Kaufman JS et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-1170
    CrossrefGoogle Scholar
  • 19 Marz W, Meinitzer A, Drechsler C et al. Homoarginine, cardiovascular risk, and mortality. Circulation 2010; 122: 967-975
    CrossrefGoogle Scholar
  • 20 Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an ,uraemic toxin' to a global cardiovascular risk molecule. Eur J Clin Invest 2005; 35: 71-79
    CrossrefGoogle Scholar